Key Stats for Tango Therapeutics Stock
- Price change for Tango Therapeutics stock: 53%
- $TNGX Share Price as of Jun. 8: $31
- 52-Week High: $33
- $TNGX Stock Price Target: $34
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Tango Therapeutics (TNGX) stock exploded higher on Monday, jumping more than 50% to an all-time high. The reason was strong early data from a cancer trial.
Here’s the simple version. Tango is testing a drug called vopimetostat alongside Revolution Medicines’ drug daraxonrasib.
The target is metastatic pancreatic cancer, one of the hardest cancers to treat. In the trial, 92% of patients saw their tumors shrink.
The combination also reached a 100% disease control rate across 12 patients, with 90% still alive without their disease worsening at six months.
Those numbers are unusually high for this disease. And it gets better. The combo was also well tolerated. There were no Grade 4 or 5 side effects, and no patients stopped treatment.
This matters because pancreatic cancer is almost always treated with harsh chemotherapy. Tango wants to offer a chemo-free option instead.
Based on these results, the company plans to advance the combination to a late-stage Phase 3 trial in first-line patients.
A second drug pairing, vopimetostat with zoldonrasib, was weaker but still solid, with a 52% response rate.
See analysts’ growth forecasts and price targets for Tango Therapeutics stock (It’s free) >>>
What the Market Is Telling Us About Tango Therapeutics Stock
A 50% one-day pop tells you investors think this could be a big deal. The move stood out even more because the rest of the market was down hard on Monday. Tango Therapeutics stock went up while the Nasdaq fell over 4%.
Wall Street piled in too. Wolfe Research upgraded the stock to Outperform with a $35 target. Other firms have pushed targets even higher.
Now the caution. This is still early data in a small group of patients.
Phase 3 results are what really count, and those take time. Tango Therapeutics stock is also a classic high-risk biotech that can swing 10% to 15% in a single day.
The good news is the balance sheet. With about $380 million in cash and runway into 2028, the company has time to run its trials. For now, Tango Therapeutics stock is riding a wave of genuine optimism.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Tango Therapeutics Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
